Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Net Cash Flow (2019 - 2025)

Benitec Biopharma's Net Cash Flow history spans 7 years, with the latest figure at $40.7 million for Q1 2025.

  • For Q1 2025, Net Cash Flow rose 737.16% year-over-year to $40.7 million; the TTM value through Mar 2025 reached $104.7 million, up 1282.41%, while the annual FY2024 figure was $48.4 million, 2524.92% up from the prior year.
  • Net Cash Flow for Q1 2025 was $40.7 million at Benitec Biopharma, up from $10.1 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $40.7 million in Q1 2025 and bottomed at -$6.4 million in Q1 2024.
  • The 5-year median for Net Cash Flow is -$3.3 million (2021), against an average of $6.1 million.
  • The largest annual shift saw Net Cash Flow plummeted 163.62% in 2022 before it skyrocketed 998.19% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at -$3.3 million in 2021, then tumbled by 77.42% to -$5.9 million in 2022, then grew by 9.75% to -$5.3 million in 2023, then surged by 291.98% to $10.1 million in 2024, then surged by 301.3% to $40.7 million in 2025.
  • Per Business Quant, the three most recent readings for BNTC's Net Cash Flow are $40.7 million (Q1 2025), $10.1 million (Q4 2024), and $17.1 million (Q3 2024).